Cimicifugoside H-1

Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss[1][2][3].

Product Specifications

CAS Number

[163046-73-9]

Product Name Alternative

Cimicidanol-3-O-β-d-xyloside

UNSPSC

12352005

Target

Others

Type

Natural Products

Related Pathways

Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/cimicifugoside-h-1.html

Purity

99.83

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@]23[C@@]4([C@@](C(C)([C@H](CC4)O[C@H]5[C@@H]([C@H]([C@@H](CO5)O)O)O)C)([H])CC=C3[C@]6([C@](C1)([C@@](C(C6)=O)([H])[C@H](C)CC([C@H]7C(C)(O7)C)=O)C)C)C2

Molecular Formula

C35H52O9

Molecular Weight

616.78

References & Citations

[1]Koeda M, et, al. Studies on the Chinese crude drug "shoma." IX. Three novel cyclolanostanol xylosides, cimicifugosides H-1, H-2 and H-5, from cimicifuga rhizome. Chem Pharm Bull (Tokyo) . 1995 May;43 (5) :771-6.|[2]Gai YY, et, al. Pharmacokinetics and bioavailability of cimicifugosides after oral administration of Cimicifuga foetida L. extract to rats. J Ethnopharmacol. 2012 Aug 30;143 (1) :249-55.|[3]Li JX, et, al. Triterpenoids from Cimicifugae rhizoma, a novel class of inhibitors on bone resorption and ovariectomy-induced bone loss. Maturitas. 2007 Sep 20;58 (1) :59-69.